Lazolvan tablets 30 mg. №20


Manufacturer: Greece

Secretolytic therapy for acute and chronic bronchopulmonary diseases associated with violation of bronchial secretion and weakening of mucus promotion.



Lazolvan Composition
active substance: ambroxol hydrochloride;

1 tablet contains ambroxol hydrochloride 30 mg;

excipients: lactose monohydrate, corn starch silicon dioxide colloidal magnesium stearate.

Lazolvan Dosage form

Basic physical and chemical properties: round, white or slightly yellowish tablets, flat on both sides, with beveled edges on one side of the tablet – a line and marking “67C” on both sides of the line, on the other side of the tablet the brand name is displaced.

Lazolvan Pharmacotherapeutic group
Drugs used for coughs and colds. Mucolytic agents. ATX code R05C B06.

Lazolvan Pharmacodynamics
It has been preclinically proven that the active substance of the drug Lazolvan®, tablets – ambroxol hydrochloride – increases the formation of the serous component of the bronchial secretion. Ambroxol enhances the release of pulmonary surfactant by direct action on type II pneumocytes in the alveoli and Clara cells in the bronchioles, and also stimulates ciliary activity, resulting in reduced sputum viscosity and improved excretion (mucociliary clearance). Improving mucociliary clearance has been proven during clinical and pharmacological studies.

Increased production of serous secretions and increased mucociliary clearance facilitate expectoration and reduce coughing.

In patients with COPD who received ambroxol hydrochloride, 75 mg capsules for 6 months, there was a significant decrease in the number of exacerbations compared with placebo at the end of 2 months of treatment. Patients who were treated with ambroxol hydrochloride had significantly fewer days of illness and needed fewer days of antibiotic therapy. They also showed statistically significant reductions in symptoms such as difficulty with expectoration, coughing, shortness of breath, and auscultatory sounds compared with placebo.

Absorption. Absorption of ambroxol hydrochloride from oral forms of immediate release is rapid and complete, with a linear dose dependence in the therapeutic range. The maximum level in blood plasma is reached after 1-2.5 hours with oral administration of rapid-release dosage forms and, on average, after 6.5 hours with the use of slow-release forms.

Bioavailability after taking a 30 mg tablet is 79%.

Distribution. When taken orally, the distribution of ambroxol hydrochloride from the blood to the tissues is rapid and pronounced, with a high concentration of the active substance in the lungs. The expected volume of distribution for oral administration is 552 liters. In blood plasma in the therapeutic dose range, approximately 90% of the drug binds to proteins.

Secretolytic therapy for acute and chronic bronchopulmonary diseases associated with impaired bronchial secretion and weakening of mucus movement.

Lazolvan® should not be used in patients with hypersensitivity to ambroxol hydrochloride or other components of the drug.